Lamictal (lamotrigine) Chewable Dispersible Tablet
Company: GlaxoWellcome
Approval Status: Approved June 1999
Treatment for: Neurology
Areas: Neurology
Possible similar drugs: Lamictal Chewable Dispersible Tablets
General Information
Other Useful Resources
The approval of these efficacy supplements provide for the use of Lamictal as conversion to monotherapy in adults with partial seizures who are receiving treatment with a single enzyme-inducing antiepileptic drug.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
